Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Utility of Biomarkers in Evaluating Responsiveness to Anti-IgE (Omalizumab) in Severe Asthma Patients

NCT03361111 is registered in ClinicalTrials.gov with Medical University of Warsaw as lead sponsor.

NCT NCT03361111
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03361111 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Utility of Biomarkers in Evaluating Responsiveness to Anti-IgE (Omalizumab) in Severe Asthma Patients
Lead sponsor
Medical University of Warsaw
Phase
Observational
Overall status
Completed
Start date
April 4, 2013
Completion date
December 30, 2018
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

severe asthma